Indian pharmaceutical companies may be impacted if US decides to implement the proposed border adjustment tax (BAT).
According to analysts the adjustment will be “detrimental” to Indian companies exporting to the US and may erode the profitability by 17-46%, if the bill is passed in the present format.
India contributes around 30% of the overall volume of drugs consumed in US with generic companies, including Sun Pharma, Lupin and Glenmark, exporting around 40% of their overall sales.
